Pfizer’s TUKYSA Regimen Obtains FDA Approval As Front-Line Maintenance Treatment For HER2+ Metastatic Breast Cancer

Pfizer Inc. (NYSE: PFE) has received FDA approval for TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a front-line maintenance treatment for adults with unresectable locally advanced or metastatic HER2+ breast cancer. This approval is based on a study showing over 50% improvement in median progression-free survival, providing a new chemotherapy-free option for patients to delay disease progression.